A Phase II Exploratory, Open-label Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00261053 Phase 2 COMPLETED

The purpose of this single-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.

Details

Lead sponsor	Pharming Technologies B.V.
Phase	Phase 2
Status	COMPLETED
Enrolment	14
Start date	2003-06
Completion	2005-12

Conditions

• Genetic Disorders

Interventions

• i.v. recombinant human C1 inhibitor

Primary outcomes

• Primary outcomes: Relief of angioedema symptoms

Countries

Netherlands